QURE

uniQure N.V.

4.53 USD
-0.06 (-1.31%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

uniQure N.V. stock is down -4.83% since 30 days ago. The next earnings date is Jul 30, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 45.45% of the previous 10 June’s closed higher than May. In the last 7 Unusual Options Trades, there were 7 CALLs.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
03 May 14:07 21 Jun, 2024 5.00 CALL 577 123
09 May 16:50 17 May, 2024 5.00 CALL 1769 793
09 May 16:50 17 May, 2024 5.00 CALL 1783 793
16 May 18:50 21 Jun, 2024 5.00 CALL 1999 975
16 May 19:35 21 Jun, 2024 5.00 CALL 1649 975
22 May 19:54 21 Jun, 2024 5.00 CALL 2000 4956
03 Jun 16:04 21 Jun, 2024 5.00 CALL 1041 6785

About uniQure N.V.

uniQure N.V. engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in clinical study for Huntington's disease.